Zilucoplan

Summary

Zilucoplan is a prescription‑only macrocyclic peptide that inhibits complement component C5. It is administered by subcutaneous injection and is approved for the treatment of acetylcholine‑receptor‑positive generalized myasthenia gravis (gMG). By blocking the terminal complement pathway, it reduces complement‑mediated damage at the neuromuscular junction, improving muscle strength and daily functioning.

Mechanism of Action

Zilucoplan binds directly to complement protein C5, preventing its cleavage into C5a and C5b. This stops formation of the membrane‑attack complex (C5b‑9) and the release of the pro‑inflammatory C5a fragment. In gMG, where auto‑antibodies trigger complement activation at the postsynaptic muscle membrane, this blockade limits complement‑driven injury and preserves neuromuscular transmission.

What the Research Shows

Reviews of anti‑C5 agents list zilucoplan among newer complement inhibitors under clinical evaluation for both paroxysmal nocturnal hemoglobinuria and myasthenia gravis. A systematic review and network meta‑analysis of innovative MG therapies incorporated 12‑week data from the phase 3 RAISE trial, showing a mean MG‑ADL improvement of –4.39 points versus –2.30 with placebo. The RAISE study, a double‑blind, placebo‑controlled trial in 174 patients, demonstrated statistically significant and clinically meaningful reductions in MG‑ADL and QMG scores, with a safety profile comparable to placebo. Long‑term outcomes are being explored in an open‑label extension, while data for PNH remain limited to ongoing studies.

Reported Benefits

Evidence from the RAISE trial indicates that zilucoplan provides rapid, clinically meaningful improvement in daily‑living activities and quantitative strength scores for patients with AChR‑positive gMG. Its subcutaneous, once‑daily self‑administration offers greater convenience than intravenous anti‑C5 antibodies. Meta‑analytic data suggest anti‑complement therapy, including zilucoplan, is effective compared with placebo and comparable to other novel MG agents, expanding therapeutic options for patients inadequately controlled by conventional immunosuppression.

Limitations of the Evidence

Efficacy data are limited to a 12‑week randomized trial; long‑term durability, optimal treatment duration, and real‑world effectiveness remain uncertain. Direct head‑to‑head comparisons with other complement inhibitors or FcRn blockers are lacking. Evidence for use in other complement‑mediated diseases such as PNH is still experimental. The need for meningococcal vaccination and the potential for breakthrough hemolysis under stress are not fully addressed in the current literature.

Safety Considerations

In the RAISE trial, treatment‑emergent adverse events occurred in 77 % of zilucoplan recipients versus 70 % of placebo, most commonly injection‑site bruising. Serious adverse events and infections were similar between groups, and no deaths were attributed to the drug. As with all complement inhibitors, vaccination against Neisseria meningitidis is recommended to mitigate infection risk. Overall, the safety profile was judged favourable and comparable to placebo over the 12‑week period.

How It Is Administered

Zilucoplan is supplied for subcutaneous injection and is self‑administered once daily, typically at a dose of 0.3 mg/kg as used in the phase 3 RAISE study. The formulation is a sterile solution intended for subcutaneous use; no oral or intravenous routes are described in the approved labeling.

Routes of Administration

Goals & Uses

• Generalized Myasthenia GravisAutoimmune Neuromuscular DiseaseModerate
• Complement inhibitionImmunology/inflammationHigh
• Reduction of neuromuscular junction damageNeuroprotectionHigh
• Treatment of generalized myasthenia gravis (gMG)Neuromuscular DiseaseHigh

Contraindications

• Lack of meningococcal vaccination prior to initiationInfection PreventionHigh
• Unresolved Neisseria meningitidis infectionInfectious DiseaseHigh
• Known hypersensitivity to Zilucoplan or any excipientAllergyHigh

Adverse Effects

• Injection site reactionsLocalCommon
• HeadacheNeurologicCommonPain in the head or upper neck
• Serious infections (meningococcal)InfectionRare
• Upper respiratory tract infectionInfectiousUncommon
• DiarrheaGastrointestinalCommonLoose or frequent stools
• Injection site erythemaLocalCommonRedness at the injection site

Drug Interactions

• Live vaccinesModerate
• Other immunosuppressantsModerate

Population Constraints

• PregnancyReproductive SafetyRelative
• Pediatric patientsAgeRelative
• Patients with active systemic infectionsInfectious DiseaseRelative
• Pregnant or breastfeeding womenReproductiveRelative

Regulatory Status

• European UnionInvestigationalUnder EMA review; no marketing authorization.
• United StatesInvestigationalPhase 3 trials ongoing; not FDA‑approved.
• United KingdomInvestigationalMHRA has granted clinical trial permission only.

As of 2024 the product remains in Phase 3 trials; no regulatory approval in the US, EU, or UK.

Evidence & Sources

• Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy
  Journal ArticleModerateVersino F, Fattizzo B2024-01-01T00:00:00.000000Z
• Myasthenia Gravis Treatment: From Old Drugs to Innovative Therapies with a Glimpse into the Future
  Journal ArticleModerateCrisafulli S, et al.2024-01-01T00:00:00.000000Z
• Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta-analysis and network meta-analysis
  Journal ArticleHighSaccà F, et al.2023-01-01T00:00:00.000000Z
• Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study
  Journal ArticleModerateHoward JF Jr, et al.2023-01-01T00:00:00.000000Z
• Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals
  Journal ArticleModerateMenon D, Bril V2022-01-01T00:00:00.000000Z
• Targeted Treatments for Myasthenia Gravis in Children and Adolescents
  Journal ArticleModerateRamdas S, et al.2024-01-01T00:00:00.000000Z

Frequently Asked Questions